logo-loader
viewInternational Business Machines Corp.

IBM shares plunge as it reports fifth consecutive quarter of declining revenue

In the third quarter to September 30, group revenue came in at US$18.03 billion compared to analysts' expectations of US$18.22 billion

International Business Machines Corp. -
IBM said it is expecting adjusted earnings of at least US$12.80 for the whole year

IBM Corp (NYSE:IBM) shares plunged in New York after the computer titan posted its fifth consecutive quarter of declining revenue as an uptick in revenue in cloud-based activity has not been able to counter falls in sales in the hardware and services businesses. 

In the third quarter to September 30, group revenue came in at US$18.03 billion compared to analysts' expectations of US$18.22 billion. Meanwhile, net income in the three months, excluding items, was slightly ahead of expectations at US$2.68  per share, compared to Wall Street forecasts of US$2.67.

Revenue from the cloud-based business for the quarter, which includes software multinational Red Hat, which IBM acquired earlier this year, was US$5.28 billion, up 11%, but analysts had pencilled in US$5.43 billion.

The group's Global Technology Services arm, or 'GTS', posted US$6.7 billion in revenue compared with US$6.77 billion Wall Street consensus.

IBM expects adjusted earnings of at least US$12.80 for the year as a whole, while analysts are expecting US$12.80.

Shares lost 6.14% in New York to stand at US$133.32 each.

Quick facts: International Business Machines Corp.

Price: 134.52 USD

NYSE:IBM
Market: NYSE
Market Cap: $119.14 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model. Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket...

31 minutes ago

2 min read